Davis IJ - Search Results

1

Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers.

Davis IJ, Kim JJ, Ozsolak F, Widlund HR, Rozenblatt-Rosen O, Granter SR, Du J, Fletcher JA, Denny CT, Lessnick SL, Linehan WM, Kung AL, Fisher DE. Davis IJ, et al. Cancer Cell. 2006 Jun;9(6):473-84. doi: 10.1016/j.ccr.2006.04.021. Cancer Cell. 2006. PMID: 16766266 Free article.

2

A tissue-restricted cAMP transcriptional response: SOX10 modulates alpha-melanocyte-stimulating hormone-triggered expression of microphthalmia-associated transcription factor in melanocytes.

Huber WE, Price ER, Widlund HR, Du J, Davis IJ, Wegner M, Fisher DE. Huber WE, et al. Among authors: davis ij. J Biol Chem. 2003 Nov 14;278(46):45224-30. doi: 10.1074/jbc.M309036200. Epub 2003 Aug 27. J Biol Chem. 2003. PMID: 12944398 Free article.

3

MiT transcription factor associated malignancies in man.

Davis IJ, Fisher DE. Davis IJ, et al. Cell Cycle. 2007 Jul 15;6(14):1724-9. doi: 10.4161/cc.6.14.4484. Epub 2007 May 24. Cell Cycle. 2007. PMID: 17630504 Review.

4

Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma.

Davis IJ, McFadden AW, Zhang Y, Coxon A, Burgess TL, Wagner AJ, Fisher DE. Davis IJ, et al. Cancer Res. 2010 Jan 15;70(2):639-45. doi: 10.1158/0008-5472.CAN-09-1121. Epub 2010 Jan 12. Cancer Res. 2010. PMID: 20068147 Free PMC article.

5

Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation.

Davis IJ, Hsi BL, Arroyo JD, Vargas SO, Yeh YA, Motyckova G, Valencia P, Perez-Atayde AR, Argani P, Ladanyi M, Fletcher JA, Fisher DE. Davis IJ, et al. Proc Natl Acad Sci U S A. 2003 May 13;100(10):6051-6. doi: 10.1073/pnas.0931430100. Epub 2003 Apr 28. Proc Natl Acad Sci U S A. 2003. PMID: 12719541 Free PMC article.

6

Sumoylation of MITF and its related family members TFE3 and TFEB.

Miller AJ, Levy C, Davis IJ, Razin E, Fisher DE. Miller AJ, et al. Among authors: davis ij. J Biol Chem. 2005 Jan 7;280(1):146-55. doi: 10.1074/jbc.M411757200. Epub 2004 Oct 25. J Biol Chem. 2005. PMID: 15507434 Free article.

7

Inhibition of the met receptor in mesothelioma.

Mukohara T, Civiello G, Davis IJ, Taffaro ML, Christensen J, Fisher DE, Johnson BE, Jänne PA. Mukohara T, et al. Among authors: davis ij. Clin Cancer Res. 2005 Nov 15;11(22):8122-30. doi: 10.1158/1078-0432.CCR-05-1191. Clin Cancer Res. 2005. PMID: 16299245

8

TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition.

Tsuda M, Davis IJ, Argani P, Shukla N, McGill GG, Nagai M, Saito T, Laé M, Fisher DE, Ladanyi M. Tsuda M, et al. Among authors: davis ij. Cancer Res. 2007 Feb 1;67(3):919-29. doi: 10.1158/0008-5472.CAN-06-2855. Cancer Res. 2007. PMID: 17283122

9

Upper respiratory tract carcinoma with chromosomal translocation 15;19: evidence for a distinct disease entity of young patients with a rapidly fatal course.

Vargas SO, French CA, Faul PN, Fletcher JA, Davis IJ, Dal Cin P, Perez-Atayde AR. Vargas SO, et al. Among authors: davis ij. Cancer. 2001 Sep 1;92(5):1195-203. doi: 10.1002/1097-0142(20010901)92:5<1195::aid-cncr1438>3.0.co;2-3. Cancer. 2001. PMID: 11571733

10

Validation of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinomas.

Mosquera JM, Dal Cin P, Mertz KD, Perner S, Davis IJ, Fisher DE, Rubin MA, Hirsch MS. Mosquera JM, et al. Among authors: davis ij. Diagn Mol Pathol. 2011 Sep;20(3):129-37. doi: 10.1097/PDM.0b013e31820e9c67. Diagn Mol Pathol. 2011. PMID: 21817901

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

148 results

Search Page